Skip to main content

Vericiguat Dosage

Medically reviewed by Drugs.com. Last updated on Feb 4, 2021.

Applies to the following strengths: 2.5 mg; 5 mg; 10 mg

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Heart Failure

Initial dose: 2.5 mg orally once a day
Maintenance dose: The dose should be doubled about every 2 weeks to reach the target dose of 10 mg orally once a day, as tolerated by the patient.

Use: To reduce the risk of cardiovascular death and heart failure (HF) hospitalization after a hospitalization for HF or need for outpatient IV diuretics, in patients with symptomatic chronic HF and ejection fraction less than 45%

Renal Dose Adjustments

Estimated GFR at least 15 mL/min/1.73 m2 (not on dialysis): No adjustment recommended.
Estimated GFR less than 15 mL/min/1.73 m2: Data not available

Comments:
-This drug has not been studied in patients with estimated GFR less than 15 mL/min/1.73 m2 at treatment initiation.

Liver Dose Adjustments

Mild or moderate liver dysfunction (e.g., Child-Pugh A or B): No dose adjustment recommended.
Severe liver dysfunction (e.g., Child-Pugh C): Data not available

Comments:
-This drug has not been studied in patients with severe liver dysfunction.

Precautions

US BOXED WARNING:
-EMBRYOFETAL TOXICITY: Because this drug may cause fetal harm, it should not be administered to a pregnant patient. Pregnancy should be excluded in patients of childbearing potential before treatment initiation. To prevent pregnancy, patients of childbearing potential must use effective contraception during therapy and for 1 month after the last dose.

CONTRAINDICATIONS:
-Pregnancy
-Concomitant use with other soluble guanylate cyclase (sGC) stimulators

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Comments:
-This drug has not been studied in patients on dialysis.
-This drug is unlikely to be removed by hemodialysis due to high protein binding.

Other Comments

Administration advice:
-Before starting therapy, obtain a pregnancy test in patients of childbearing potential.
-Administer with food.
-Tablets may be crushed and mixed with water immediately before administration for patients unable to swallow whole tablets.

Storage requirements:
-Store at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F).

Monitoring:
-General: For pregnancy (before starting therapy)

Patient advice:
-Read the US FDA-approved patient labeling (Medication Guide).
-If a dose is missed, take it as soon as you remember on the same day of the missed dose; do not take 2 doses on the same day.
-Inform health care provider of known/suspected pregnancy; if exposed to this drug during pregnancy, report the pregnancy to your health care provider.
-Patients of childbearing potential: Use effective contraception during therapy and for 1 month after the last dose.
-Do not breastfeed during therapy.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.